90 related articles for article (PubMed ID: 20832295)
1. C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors?
Wethal T; Haugnes HS; Kjekshus J; Småstuen MC; Ueland T; Aukrust P; Fosså SD
Eur J Cancer; 2010 Dec; 46(18):3425-33. PubMed ID: 20832295
[TBL] [Abstract][Full Text] [Related]
2. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue.
Orre IJ; Murison R; Dahl AA; Ueland T; Aukrust P; Fosså SD
Brain Behav Immun; 2009 Aug; 23(6):868-74. PubMed ID: 19362138
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.
Haugnes HS; Wethal T; Aass N; Dahl O; Klepp O; Langberg CW; Wilsgaard T; Bremnes RM; Fosså SD
J Clin Oncol; 2010 Oct; 28(30):4649-57. PubMed ID: 20855830
[TBL] [Abstract][Full Text] [Related]
4. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study.
Jeppesen J; Hansen TW; Olsen MH; Rasmussen S; Ibsen H; Torp-Pedersen C; Hildebrandt PR; Madsbad S
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):594-8. PubMed ID: 18753952
[TBL] [Abstract][Full Text] [Related]
5. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study.
Lee DS; Evans JC; Robins SJ; Wilson PW; Albano I; Fox CS; Wang TJ; Benjamin EJ; D'Agostino RB; Vasan RS
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):127-33. PubMed ID: 17095717
[TBL] [Abstract][Full Text] [Related]
6. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.
van den Belt-Dusebout AW; de Wit R; Gietema JA; Horenblas S; Louwman MW; Ribot JG; Hoekstra HJ; Ouwens GM; Aleman BM; van Leeuwen FE
J Clin Oncol; 2007 Oct; 25(28):4370-8. PubMed ID: 17906202
[TBL] [Abstract][Full Text] [Related]
7. Detection of second malignancies during long-term follow-up of testicular cancer survivors.
Buchler T; Kubankova P; Boublikova L; Donatova Z; Foldyna M; Kanakova J; Kordikova D; Kupec M; Nepomucka J; Vorsilkova E; Abrahamova J
Cancer; 2011 Sep; 117(18):4212-8. PubMed ID: 21480199
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study.
Wilson PW; Nam BH; Pencina M; D'Agostino RB; Benjamin EJ; O'Donnell CJ
Arch Intern Med; 2005 Nov; 165(21):2473-8. PubMed ID: 16314543
[TBL] [Abstract][Full Text] [Related]
9. Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases.
Hamer M; Chida Y; Stamatakis E
Am J Cardiol; 2009 Aug; 104(4):538-42. PubMed ID: 19660608
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study.
Siemes C; Visser LE; Coebergh JW; Splinter TA; Witteman JC; Uitterlinden AG; Hofman A; Pols HA; Stricker BH
J Clin Oncol; 2006 Nov; 24(33):5216-22. PubMed ID: 17114654
[TBL] [Abstract][Full Text] [Related]
11. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
[TBL] [Abstract][Full Text] [Related]
12. Positive correlation of CRP and fibrinogen levels as cardiovascular risk factors in early stage of continuous ambulatory peritoneal dialysis patients.
Tekin IO; Pocan B; Borazan A; Ucar E; Kuvandik G; Ilikhan S; Demircan N; Ozer C; Kadayifci S
Ren Fail; 2008; 30(2):219-25. PubMed ID: 18300125
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Li JJ; Fang CH
Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein: an independent predictor of cardiovascular disease in Aboriginal Australians.
Wang Z; Hoy WE
Aust N Z J Public Health; 2010 Jul; 34 Suppl 1():S25-9. PubMed ID: 20618287
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein: a nontraditional serum marker of cardiovascular risk.
de Ferranti SD; Rifai N
Cardiovasc Pathol; 2007; 16(1):14-21. PubMed ID: 17218210
[TBL] [Abstract][Full Text] [Related]
16. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
Nordestgaard BG; Zacho J
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
[TBL] [Abstract][Full Text] [Related]
17. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population.
Romero-Corral A; Sierra-Johnson J; Lopez-Jimenez F; Thomas RJ; Singh P; Hoffmann M; Okcay A; Korinek J; Wolk R; Somers VK
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5(7):418-25. PubMed ID: 18431365
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein: a new risk assessment tool for cardiovascular disease.
Clearfield MB
J Am Osteopath Assoc; 2005 Sep; 105(9):409-16. PubMed ID: 16239491
[TBL] [Abstract][Full Text] [Related]
19. Additive effect of interleukin-6 and C-reactive protein (CRP) single nucleotide polymorphism on serum CRP concentration and other cardiovascular risk factors.
Paik JK; Kim OY; Koh SJ; Jang Y; Chae JS; Kim JY; Kim HJ; Hyun YJ; Cho JR; Lee JH
Clin Chim Acta; 2007 May; 380(1-2):68-74. PubMed ID: 17335789
[TBL] [Abstract][Full Text] [Related]
20. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
Honda H; Qureshi AR; Heimbürger O; Barany P; Wang K; Pecoits-Filho R; Stenvinkel P; Lindholm B
Am J Kidney Dis; 2006 Jan; 47(1):139-48. PubMed ID: 16377395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
